Atrag
Atrag Uses, Dosage, Side Effects, Food Interaction and all others data.
Atrag, a tertiary amine antimuscarinic, produces dilation and loss of accommodation by blocking the response of iris sphincter muscle and the accommodative ciliary muscle to cholinergic stimulation.
Atrag is an anticholinergic drug that produces typical anticholinergic effects inducing mydriasis and cycloplegia. Other effects of structurally-related atropine that could also apply to homatropine include inhibition of secretions, tachycardia, relaxation of smooth muscle and central nervous effects including excitation .
Trade Name | Atrag |
Availability | Prescription only |
Generic | Homatropine |
Homatropine Other Names | Homatropina, Omatropina |
Related Drugs | Humira, dexamethasone ophthalmic, triamcinolone ophthalmic, azathioprine, atropine ophthalmic, cyclopentolate ophthalmic, Cyclogyl, Isopto Atropine, Mydriacyl, Tropicacyl |
Type | Injection |
Formula | C16H21NO3 |
Weight | Average: 275.348 Monoisotopic: 275.15214354 |
Protein binding | No pharmacokinetic data available. |
Groups | Approved |
Therapeutic Class | Mydriatic and Cycloplegic agents |
Manufacturer | Agron Remedies |
Available Country | India |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Atrag Hydrobromide sterile Eye Drops is used for use as a mydriatic and cycloplegic agent.
Atrag is also used to associated treatment for these conditions: Strabismus
How Atrag works
Atrag is a competitive muscarinic receptor antagonist with a bulky aromatic group in place of the acetyl group of acetylcholine. It is expected to act in similar manner as atropine, producing similar parasympatholytic effects. By blocking muscarinic receptors and cholinergic signalling pathways, homatropine blocks the response of the iris sphincter muscle and cause the pupil to become unresponsive to light upon dilation or mydriasis. It also blocks the accommodative muscle of the ciliary body to cholinergic stimulation .
Dosage
Atrag dosage
Mydriasis and cycloplegia for refraction:
- Adult: Instill 1 or 2 drops of 2% solution, or 1 drop of 5% solution immediately before the procedure, repeat at 5-10 minute intervals if necessary.
- Child: Instill 1 drop of 2% soln immediately before the procedure, repeat at 10-min intervals if necessary.
Uveitis:
- Adult: Instill 1-2 drops of 2% or 5% solution bid-tid up to every 3-4 hr as needed.
- Child: 3 mth- 2 yr: instill 1 drop of 0.5% soln once daily or on alternate days. >2 yr: instill 1 drop of 1% or 2% soln bid.
Side Effects
Hypersensitivity may occur as conjunctivitis.
Toxicity
Acute oral LD50 is 1200 mg/kg in rat, 1400 mg/kg in mouse, and 1000 mg/kg in guinea pig . Systemic toxicity may occur following topical overdose of structurally-related ophthalmic atropine, particularly in children. It is characterized by flushing and dryness of the skin, blurred vision, a rapid and irregular pulse, fever, convulsions and hallucinations, and the loss of neuromuscular coordination. Abdominal distension may be observed with infants. Severe intoxication is manifested by central nervous system depression, coma, circulatory and respiratory failure, and death . Symptomatic and supportive treatment should be initiated. In case of accidental use or overdose in infants and small children, the body surface should be kept moist .
Precaution
Should be used with caution in patients with prostatic enlargement and in patients suffering from paralytic ileus or pyloric stenosis.
Interaction
Effects may be increased by drugs with antimuscarinic effect such as; some antihistamines; phenothiazines; antipsychotics; TCAs; MAOIs or parasympathomimetics.
Food Interaction
No interactions found.Atrag Disease Interaction
Volume of Distribution
No pharmacokinetic data available.
Elimination Route
No pharmacokinetic data available.
Half Life
No pharmacokinetic data available.
Clearance
No pharmacokinetic data available.
Elimination Route
No pharmacokinetic data available.
Pregnancy & Breastfeeding use
Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Matropin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in lactation: It is not known whether Atrag is excreted in human milk. Caution should be exercised when Matropin is administered to a nursing mother.
Contraindication
Contraindicated in patients with closed-angle glaucoma or with a narrow angle between the iris and the cornea.
Special Warning
Use in children: Should not be used in children below the age of 3 months
Acute Overdose
Ataxia, incoherent speech, restlessness, hallucinations, disorientation, failure to recognize people and tachycardia. Psychotic reactions and behavioural disturbances (in children). SC/IM/IV Physostigmine salicylate 1-2 mg to control central and peripheral effects. Small doses of short-acting barbiturate eg. thiopentone sodium 100 mg to control excitement.
Innovators Monograph
You find simplified version here Atrag
Atrag contains Homatropine see full prescribing information from innovator Atrag Monograph, Atrag MSDS, Atrag FDA label